FindTrial
Sign In

A comparative study between efficacy of topical JAK inhibitor alone versus JAK inhibitor with phototherapy in vitiligo patients

A comparison between efficacy of topical JAK inhibitors alone versus topical JAK inhibitor with phototherapy in vitiligo patients in a tertiary health care centre: An open labelled study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070001
Enrollment
30
Registered
2024-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: topical tofacitinib 2% cream: topical tofacitinib 2% cream will be applied twice a day for 3 months at the vitiligo patches in one arm Control Intervention1: topical tofacitinib 2% crea

Sponsors

Dr Sneha Ulhaskumar Arakeri
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of vitiligo with = 2 depigmented patches (not on the mucosa) each =10% BSA

Exclusion criteria

Exclusion criteria: Patients with mucosal lesions

Design outcomes

Primary

MeasureTime frame
to compare improvement in the pigmentation status in both armsTimepoint: at 4 weeks, 8weeks and 12 weeks—

Secondary

MeasureTime frame
to assess the re-pigmentation in the tofacitinib armTimepoint: at 12 weeks—

Countries

India

Contacts

Public ContactDr. Sneha Ulhaskumar Arakeri

Jawaharlal Nehru Medical College, KLE University

shivakumarkpatil@gmail.com9844512315

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026